Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003 (Third Quarter of Fiscal Year 2003)
Business Overview: Cardinal Health operates in four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The period includes the integration of the Syncor International Corporation acquisition completed on January 1, 2003.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Mar 31, 2003 | Nine Months Ended Mar 31, 2003 |
|---|---|---|
| Operating Revenue | $12,837.3 | $36,960.2 |
| Operating Gross Margin | $1,194.1 | $3,280.5 |
| Operating Earnings | $608.2 | $1,666.6 |
| Net Earnings | $383.1 | $1,038.9 |
| Diluted EPS (Net) | $0.84 | $2.29 |
| Cash and Equivalents (Balance Sheet) | $545.2 | N/A |
| Net Cash from Operating Activities | N/A | $515.8 |
| Long-term Obligations | $2,328.2 | N/A |
Note: Bulk deliveries to customer warehouses are reported at cost with zero gross margin and are excluded from gross margin calculations.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 11% for the quarter and 13% for the nine-month period compared to the prior year. Growth was driven by higher sales volume, new products, and the Syncor acquisition.
- Profitability: Net earnings increased 28% for the quarter ($383.1M vs. $300.3M) and 37% for the nine-month period ($1,038.9M vs. $759.9M). The prior year nine-month period included a $70.1M cumulative effect of a change in accounting.
- Special Items:
- Merger Costs: Merger-related charges decreased significantly to $15.9M for the quarter (vs. $39.1M prior year) and $49.3M for the nine months (vs. $68.2M prior year).
- Litigation Income: The company recorded $6.8M in litigation settlement income for the quarter and $99.6M for the nine months, primarily from antitrust claims against vitamin manufacturers.
- Restructuring: Charges for manufacturing facility closures totaled $21.4M for the nine months ended March 31, 2003.
- Cash Flow: Net cash provided by operating activities turned positive at $515.8M for the nine months, compared to a use of $442.8M in the prior year. This was offset by significant cash outflows for share repurchases ($1,191.7M).
Guidance, Outlook, and Risks
- Future Costs: Management estimates approximately $110 million ($70 million net of tax) in additional merger-related, restructuring, and integration costs to be incurred primarily in fiscal 2003 and 2004.
- Acquisition Integration: The Syncor acquisition is being integrated into the Pharmaceutical Technologies and Services segment. The company expects to complete the sale of Syncor's discontinued operations by January 1, 2004.
- Share Repurchases: The Board authorized a new $500 million share repurchase program in January 2003. Approximately $500 million was utilized in the quarter ended March 31, 2003.
- Legal Risks:
- Latex Litigation: 271 lawsuits pending regarding natural rubber latex exposure. Potential liability is estimated between $0 and $20 million net of insurance, though damages requested in individual cases range widely.
- Syncor Litigation: Multiple shareholder class actions and derivative suits allege improper payments by Syncor prior to acquisition. The company believes these will not have a material adverse effect.
- Market Risks: Fluctuations in bulk deliveries (zero margin) and changes in vendor policies regarding inventory management agreements (IMAs) may impact revenue mix and gross margins.
Investor Verification Checklist
- Syncor Integration: Verify the progress of integrating Syncor's nuclear pharmacy services and the timeline for selling discontinued Syncor operations.
- Special Items Impact: Assess the sustainability of earnings by excluding the $99.6M litigation settlement income and evaluating the remaining $110M in estimated future restructuring costs.
- Cash Utilization: Review the impact of the $1.2 billion share repurchase program on liquidity and future capital allocation.
- Margin Trends: Monitor gross margin percentages, particularly in the Pharmaceutical Distribution segment, which declined due to a shift toward lower-margin customers and changes in vendor programs.
- Legal Exposure: Track developments in the latex litigation and Syncor-related shareholder suits to ensure the "immaterial" assessment remains valid.